Harrow, Inc. heads into its Q1 2026 earnings today with a short book that remains stubbornly elevated — and a stock that has pulled back sharply from this year's highs.
Short sellers are not backing down. At 17% of the free float, HROW's short interest ranks in the bottom 4th percentile of the broader universe — meaning almost no stock carries heavier short positioning. Days to cover have stretched to more than 17, a figure that sits in the 5th percentile: even at current trading volumes, unwinding the short would take weeks. The ORTEX short score has held near 79.6 for the past two weeks, barely moving despite a modest 3% reduction in shares short over the past month. Borrow conditions, however, have eased. The cost to borrow has fallen roughly 15% over the past month to 0.72% — well off the early-April highs above 1% — and availability has loosened meaningfully as the borrow pool has opened up. The stock itself dropped 5.4% over the past week to $38.04, and is down 22% year-to-date, leaving it well below the levels at which the CEO and CFO last sold in December 2025.
Options traders are not loading up on protection. The put/call ratio of 0.22 runs essentially in line with its 20-day average, with a z-score barely above zero. That places it near the 52-week low for defensive positioning — suggesting options market participants are not bracing for a sharp downside move, even as short sellers maintain heavy pressure. The divergence between the two signals is the central tension into this print.
The bull-bear debate centres on execution. Covering analysts are unanimously constructive — all active recommendations are Buy or Overweight — with targets ranging from $63 to $91 and a mean around $68, roughly 79% above the current price. The bull case rests on Harrow's 2026 revenue guidance of $350M–$360M, a J-code approval expected to drive adoption of a key drug, and a stated target of $250M in quarterly revenue by 2027. Bears point to a slower-than-expected IHEEZO launch, a revenue recognition shift that muddies near-term growth, and patent uncertainty that threatens future revenue streams. B. Riley trimmed its target from $74 to $65 in early April while holding its Buy, and BTIG reiterated at $63 without change — both signalling that the Street sees upside but is adjusting expectations. Quarterly revenue consensus is near $52.5M; cash flow from operations was positive at $14.5M last quarter, but net income remains negative.
The ownership picture adds nuance. Opaleye Management — the top holder at nearly 10% of shares — has been a steady seller since at least February, offloading more than $8M in stock between February and March 2026. The CEO and CFO also sold in December, at prices well above current levels. Those cumulative insider outflows, set against a stock already down sharply on the year, frame the question the Q1 report will answer: whether the revenue ramp is on track to justify the gap between where insiders have been trimming and where the stock trades today.
See the live data behind this article on ORTEX.
Open HROW on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
